Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Oramed Pharmaceuticals (ORMP) Equity Average (2016 - 2026)

Oramed Pharmaceuticals filings provide 15 years of Equity Average readings, the most recent being $201.5 million for Q4 2025.

  • Quarterly Equity Average rose 33.55% to $201.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $201.5 million through Dec 2025, up 33.55% year-over-year, with the annual reading at $173.0 million for FY2025, 11.92% up from the prior year.
  • Equity Average hit $201.5 million in Q4 2025 for Oramed Pharmaceuticals, up from $178.4 million in the prior quarter.
  • Across five years, Equity Average topped out at $201.5 million in Q4 2025 and bottomed at $38.8 million in Q1 2021.
  • Average Equity Average over 5 years is $144.5 million, with a median of $151.5 million recorded in 2022.
  • The largest annual shift saw Equity Average skyrocketed 369.25% in 2021 before it fell 14.16% in 2025.
  • Oramed Pharmaceuticals' Equity Average stood at $143.3 million in 2021, then rose by 6.15% to $152.2 million in 2022, then increased by 2.24% to $155.6 million in 2023, then fell by 3.0% to $150.9 million in 2024, then surged by 33.55% to $201.5 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Equity Average are $201.5 million (Q4 2025), $178.4 million (Q3 2025), and $146.7 million (Q2 2025).